JAZZ
Jazz Pharmaceuticals plcMarquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Bridgewater Associates 4× in & out | Q3 2023 | Q3 2025 | — | +0% |
| Maverick Capital 3× in & out | Q2 2024 | Q3 2024 | — | +0% |
| Viking Global Investors 2× in & out | Q2 2017 | Q3 2019 | — | +0% |
| Lone Pine Capital | Q2 2014 | Q3 2015 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Jazz Pharmaceuticals plc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001607737-26-000008Jun 5, 2026
- Form 40001193210-26-000013Jun 3, 2026
- Form 40001783908-26-000014Jun 1, 2026
- Form 40001805688-26-000008Jun 1, 2026
- Form 40001536639-26-000002Jun 1, 2026
- Form 40001302443-26-000008May 27, 2026
- Form 40001576068-26-000002May 27, 2026
- Form 40001193210-26-000011May 5, 2026
- Form 40001193210-26-000009Apr 3, 2026
- Form 40001193210-26-000007Mar 9, 2026
- Form 40002013156-26-000004Mar 9, 2026
- Form 40001989533-26-000011Mar 9, 2026
- Form 40001805688-26-000006Mar 9, 2026
- Form 40001737329-26-000006Mar 9, 2026
- Form 40001784606-26-000012Mar 9, 2026
Fundamentals
XBRL · Jazz Pharmaceuticals plcAnnual figures sourced directly from Jazz Pharmaceuticals plc's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Jazz Pharmaceuticals plc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- DEF 14AProxy statementJun 8, 2026
- 8-KMaterial eventMay 29, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- 10-K/AAnnual report (amended)Apr 24, 2026
- 10-KAnnual reportFeb 24, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventNov 17, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventOct 28, 2025
- 8-KMaterial eventOct 22, 2025
- 10-QQuarterly reportAug 6, 2025
- 8-KMaterial eventAug 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q4 2025 | open | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | open | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $0.00 | — | +0% |
| Point72 Asset Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2024 | open | $0.00 | — | +0% |
| Maverick Capital | Q2 2024 | Q3 2024 | $0.00 | — | +0% |
| Bridgewater Associates | Q3 2023 | Q3 2025 | $0.00 | — | +0% |
| Bridgewater Associates | Q4 2022 | Q2 2023 | $0.00 | — | +0% |
| Bridgewater Associates | Q4 2021 | Q1 2022 | $0.00 | — | +0% |
| Maverick Capital | Q1 2021 | Q1 2022 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2021 | Q2 2021 | $0.00 | — | +0% |
| Viking Global Investors | Q2 2017 | Q3 2019 | $0.00 | — | +0% |
| Viking Global Investors | Q3 2016 | Q1 2017 | $0.00 | — | +0% |
| Maverick Capital | Q2 2016 | Q3 2019 | $0.00 | — | +0% |
| Lone Pine Capital | Q2 2014 | Q3 2015 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.